Journal of Clinical Investigation, Journal Year: 2025, Volume and Issue: 135(10)
Published: May 14, 2025
Inflammatory Bowel Diseases (IBD), including Crohn's disease and ulcerative colitis, pose challenges due to their complex pathophysiology high prevalence. Despite advances in immune-targeted therapies, a substantial number of patients fail achieve mucosal healing, highlighting the need for alternative therapeutic strategies. In this issue JCI, D'Addio et al. identified another mechanism underlying impaired epithelial regeneration disease. They found that abnormal cell death intestinal stem cells, mediated by altered TMEM219 signaling, led healing. Targeting with ecto-TMEM219, which blocks its activation, restored function promoted healing vitro vivo. These findings suggest promising avenue focusing on repair. Additionally, patient-derived organoids (PDOs) emerge as valuable tool personalized treatment strategies advancing field IBD research. This study underscores importance biology developing innovative therapies.
Language: Английский